Increase in doxorubicin cytotoxicity by carvedilol inhibition of P- glycoprotein activity

Biochemical Pharmacology

Volumn 58, Issue 11, 1999, Pages 1801-1806

  Jonsson, Östen ^a   Behnam Motlagh, Parviz ^a   Persson, Mattias ^a   Henriksson, Roger ^a   Grankvist, Kjell ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Carvedilol; Doxorubicin; MDR; P glycoprotein; Vasoactive drugs; Verapamil

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCEIN; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DOXORUBICIN; GLYCOPROTEIN P; PYROGALLOL; VERAPAMIL;

ARTICLE; BREAST CANCER; CANCER THERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG RESISTANCE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARBAZOLES; CELL DIVISION; DOXORUBICIN; DRUG SYNERGISM; FLUORESCEINS; FLUORESCENCE; FREE RADICALS; HUMANS; P-GLYCOPROTEIN; PROPANOLAMINES; PYROGALLOL; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0032743612     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00262-2     Document Type: Article

References (29)

1. Djurhuus R. Multiresistens mot cytostatika-biokjemi og klinisk betydning. Farmakoterapi. 4:1991;140-151.
2. Lum B.L., Gosland M.P., Kaubisch S., Sikic B.I. Molecular targets in oncology Implications of the multidrug resistance gene . Pharmacotherapy. 13:1993;88-109.
3. Bates S.E., Regis J.I., Robey R.W., Zhan Z., Scala S., Meadows B.J. Chemoresistance in the clinic Overview 1994 . Bull Cancer. 9:(Suppl 2):1994;55s-61s.
4. Holló Z., Homolya L., Hegedus T., Sarkadi B. Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett. 383:1996;99-104.
5. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1981;1967-1972.
6. Rogan A.M., Hamilton T.C., Young R.C., Klecker R.W., Ozols R.F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science. 224:1984;994-996.
7. Jirtle R.L. Chemical modification of tumour blood flow. Int J Hyperthermia. 4:1988;355-371.
8. Goldstein L.J. Clinical reversal of drug resistance. Curr Probl Cancer. 19:1995;65-124.
9. Ford J.M., Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 42:1990;155-199.
10. Raderer M., Scheithauer W. Clinical trials of agents that reverse multidrug resistance. Cancer. 72:1993;3553-3563.
11. Zamora J.M., Pearce H.L., Beck W.T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol. 33:1988;454-462.
12. Peterson H.I. Modification of tumour blood flow - a review. Int J Radiat Biol. 60:1991;201-210.
13. Jonsson Ö., Henriksson R., Grankvist K. Interactions of cardiovascular drugs with the cytotoxicity induced by epirubicin and irradiation in vitro. Int J Oncol. 3:1993;655-659.
14. Sandström P.E., Jonsson Ö., Grankvist K., Henriksson R. Identification of potassium flux pathways and their role in the cytotoxicity of estramustine in human malignant glioma, prostatic carcinoma and pulmonary carcinoma cell lines. Eur J Cancer. 30A:1994;1822-1826.
15. Dunn C.J., Lea A.P., Wagstaff A.J. Carvedilol, a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 54:1997;161-185.
16. Morita K., Hamano S., Yoshizumi M., Oka M. Inhibitory action of carvedilol, a novel α,β-adrenoceptor antagonist, on catecholamine secretion and calcium influx in cultured bovine adrenal chromaffin cells. Biochem Pharmacol. 38:1989;4461-4465.
17. McTavish D., Campoli-Richards D., Sorkin E.M. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 45:1993;232-258.
18. Yue T.L., Cheng H.Y., Lysko P.G., McKenna P.J., Feuerstein R., Gu J.L., Lysko K.A., Davis L.L., Feuerstein G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 263:1992;92-98.
19. Lysko P.G., Lysko K.A., Yue T.L., Webb C.L., Gu J.L., Feuerstein G. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurones and in gerbil global brain ischemia. Stroke. 23:1992;1635-1636.
20. Feuerstein G.Z., Yue T.L. Myocardial protection by the novel vasodilating beta-blocker, carvedilol Potential relevance of anti-oxidant activity . J Hypertens Suppl. 11:1993;S41-S48.
21. Yue T.L., McKenna P.J., Gu J.L., Cheng H.Y., Ruffolo R.R. Jr, Feuerstein G.Z. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension. 22:1993;922-928.
22. Hackett AJ, Smith HS, Springer EL, Owens RB, Nelson-Rees WA, Riggs JL and Gardner MB, Two syngeneic cell lines from human breast tissue: The aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. J Natl Cancer Inst58: 1975-1806, 1977.
23. De la Torre M., Hao X.Y., Larsson R., Nygren P., Tsuruo T., Mannervik B., Bergh J. Characterisation of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. Anticancer Res. 13:1993;1425-1430.
24. Larsson R., Nygren P., Ekberg M., Slater L. Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia. 4:1990;567-571.
25. Gruber A., Areström I., Albertioni F., Björkholm M., Peterson C., Vitols S. Multidrug resistance (Mdr1) gene expression in peripheral blasts from patients with acute leukemia only rarely increases during disease progression after combination chemotherapy. Leuk Lymphoma. 18:1995;435-442.
26. Gruber A., Larsson R., Nygren P., Bjorkholm M., Peterson C. A non-P-glycoprotein-mediated mechanism of vincristine transport which is affected by resistance modifiers and present in chemosensitive cells. Leukemia. 8:1994;985-989.
27. Marklund S.L., Westman N.G., Lundgren E., Roos G. Copper- and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Res. 42:1982;1955-1961.
28. Hauf-Zachariou U., Blackwood R.A., Gunawardena K.A., O'Donnell J.G., Garnham S., Pfarr E. Carvedilol versus verapamil in chronic stable angina A multicentre trial . Eur J Clin Pharmacol. 52:1997;95-100.
29. Grankvist K., Henriksson R. Doxorubicin and epirubicin iron-induced generation of free radicals in vitro. A comparative study. Biosci Rep. 7:1987;653-658.